HALO
Halozyme Therapeutics Inc
110.40$
+0.5%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61.3% | 44.5% | 66.1% | 24.1% | 39.8% | 59.9% | 58.2% | 30.6% | 50.4% | 48.5% | 47.8% | 50.1% | 49.2% | |
| 10.4% | 9.8% | 11.2% | 9.6% | 7.0% | 7.5% | 7.7% | 6.9% | 5.8% | 5.9% | 9.0% | 7.1% | 6.9% | |
| 4.3% | 4.2% | 5.0% | 4.1% | 4.3% | 3.8% | 4.0% | 3.7% | 3.4% | 3.7% | 4.4% | 3.7% | 3.8% | |
| 2.8% | – | – | – | – | – | – | – | – | – | – | – | – | |
| 11.1% | -7.2% | 1.5% | -36.1% | -18.6% | -8.3% | 2.8% | -19.1% | -14.4% | -2.1% | -7.0% | -9.1% | -7.8% | |
| 1.4% | 1.1% | 1.8% | 1.1% | 0.5% | 1.0% | 0.4% | 0.5% | 0.9% | 0.3% | 1.0% | 0.9% | 0.7% | |
| -38.6% | -3.6% | -42.2% | -18.2% | -57.7% | 9.9% | -34.1% | 26.0% | 56.9% | -164.2% | -0.8% | -13.0% | -36.4% | |
| – | 5.9% | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0% | -109.7% | -0.2% | 0.0% | 0.2% | -83.9% | – | -92.2% | -11.0% | 0.0% | – | -69.2% | – | |
| – | – | – | – | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| 1.9% | -108.6% | -0.2% | 4.1% | 6.4% | -82.7% | -1.3% | -91.8% | -6.3% | 53.0% | -0.4% | -67.8% | -6.7% | |
| 24.6% | -67.8% | 23.6% | 10.0% | -11.6% | -12.9% | 22.8% | -35.1% | 101.0% | -63.3% | 46.7% | -30.8% | 6.0% | |
| 59.9% | 43.4% | 64.3% | 23.0% | 39.3% | 58.9% | 57.9% | 30.1% | 49.6% | 48.2% | 46.8% | 49.2% | 48.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.